Cardivas 3.125 tablet (Carvedilol 3.125)

Description

Cardivas 3.125 tablet (Carvedilol 3.125) — Complete Clinical and Patient Information Guide

Product Overview

Cardivas 3.125 tablet (Carvedilol 3.125) contains Carvedilol 3.125mg as its active pharmaceutical ingredient, belonging to the third-generation non-selective beta-adrenoceptor blocker + alpha-1 blocker with antioxidant activity. It is clinically indicated for heart failure with reduced ejection fraction (HFrEF) — COPERNICUS and CAPRICORN trial evidence; hypertension; post-MI LV dysfunction. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Cardivas 3.125mg is Sun Pharma’s carvedilol formulation for heart failure and hypertension management — providing the proven mortality benefits of carvedilol at a titration dose appropriate for HF initiation.

About Cardivas 3.125mg and Its Active Ingredient

Carvedilol 3.125mg is the pharmacologically active compound in Cardivas 3.125mg, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Carvedilol is a non-selective, third-generation beta-adrenoceptor blocker with additional alpha-1 adrenoceptor blocking activity and unique antioxidant properties. Non-selective beta-1 and beta-2 blockade reduces cardiac rate, contractility, and arrhythmogenesis while protecting the myocardium from catecholamine-mediated toxicity, apoptosis, and pathological hypertrophy in heart failure. Alpha-1 blockade produces peripheral and coronary vasodilation — reducing afterload and preload without the reflex tachycardia that would result from pure vasodilation alone. In heart failure, this vasodilatory beta-blockade simultaneously reduces both the elevated sympathetic drive causing cardiomyocyte damage and the peripheral vascular resistance increasing cardiac workload. The COPERNICUS and CAPRICORN trials established 35% and 23% mortality reductions respectively in HFrEF and post-MI LV dysfunction.

Clinical Indications

Cardivas 3.125 tablet (Carvedilol 3.125) is indicated for:

• Primary indication: heart failure with reduced ejection fraction (HFrEF) — COPERNICUS and CAPRICORN trial evidence; hypertension; post-MI LV dysfunction
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

HF initiation: 3.125mg twice daily for 2 weeks; double every 2 weeks as tolerated to maximum 25mg twice daily (<85kg) or 50mg twice daily (>85kg). Cardivas is the Sun Pharma brand carvedilol with wide clinical use in India.

Who Should Use Cardivas 3.125mg

Cardivas 3.125mg is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

Severe bradycardia. High-degree AV block without pacemaker. Decompensated acute heart failure. Cardiogenic shock. Severe asthma/bronchospasm (non-selective agents absolute contraindication; cardioselective agents use with extreme caution even in mild asthma). Hypersensitivity.

Drug Interactions

Insulin/antidiabetics: masking of hypoglycaemia. Digoxin: additive AV slowing. CYP2D6 inhibitors (fluoxetine): increase carvedilol levels. Calcium channel blockers (verapamil, diltiazem): severe bradycardia/AV block risk.

A complete medication review is essential before initiating Cardivas 3.125mg. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Common: Fatigue, bradycardia, cold extremities, and sleep disturbance. Uncommon: Bronchoconstriction (less with cardioselective agents; still a risk in severe asthma), sexual dysfunction, depression, dizziness. Rare: Severe bradyarrhythmia, AV block, acute heart failure decompensation.

Carvedilol-specific: postural hypotension (alpha-1 component — take with food, rise slowly). Fluid retention during HF initiation.

Special Population Considerations

Cardivas is the Sun Pharma brand carvedilol — widely prescribed for HFrEF in India. Slow titration is essential: start 3.125mg BID, double every 2 weeks only if no fluid overload or symptomatic hypotension. Never stop abruptly in HF.

Storage

Store Cardivas 3.125mg at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: How is carvedilol different from other beta-blockers for heart failure?
A: Carvedilol’s additional alpha-1 blockade produces vasodilation that reduces afterload alongside beta-1 cardiac protection. The COMET trial showed carvedilol provides greater mortality reduction than metoprolol tartrate in HFrEF (carvedilol is superior to IR metoprolol, though not established versus metoprolol succinate XL). Carvedilol’s antioxidant properties provide additional cardioprotection. However, alpha-1 blockade also means greater postural hypotension risk than cardioselective agents.

Evidence Base and Clinical Guidelines

The active ingredient in Cardivas 3.125mg has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Cardiovascular Disease Management Principles

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, responsible for approximately 18 million deaths annually. Hypertension alone affects 1.28 billion adults globally — yet only 21% achieve adequate blood pressure control. The gap between evidence-based pharmacotherapy and real-world practice represents the greatest opportunity for cardiovascular risk reduction: consistently achieving guideline-recommended blood pressure targets, lipid goals, and cardiac function optimisation through appropriate, adherent pharmacotherapy has the potential to prevent hundreds of thousands of cardiovascular events annually.

Modern antihypertensive management has evolved substantially — from the early era of single-drug therapy to the current paradigm of early combination therapy targeting multiple pathophysiological mechanisms simultaneously. Multiple large randomised controlled trials and their meta-analyses demonstrate that combination antihypertensive therapy achieves blood pressure targets more effectively than monotherapy titration, with better cardiovascular outcomes. The ACCOMPLISH trial demonstrated CCB+ACE-I superiority over diuretic+ACE-I for cardiovascular events; ONTARGET established ARB equivalence to ACE-I; MERIT-HF, COPERNICUS, CIBIS-II, and EMPHASIS-HF established beta-blocker and MRA therapy for HFrEF. This robust evidence base is incorporated into ESC, ACC/AHA, and NICE guidelines that inform contemporary prescribing decisions.

Fixed-Dose Combination Therapy: Adherence and Outcomes

Non-adherence to antihypertensive therapy is the single most common reason for inadequate blood pressure control in treated patients — affecting approximately 50% of patients within the first year of treatment. Fixed-dose combinations (FDCs) address this critical problem by reducing pill burden, simplifying regimens, and improving convenience. Multiple meta-analyses confirm that FDC antihypertensive therapy significantly improves adherence compared to equivalent separate tablets, translating to better blood pressure control and improved cardiovascular outcomes.

The products in this range — spanning beta-blockers with CCBs, ARBs with CCBs and diuretics, triple combinations, and specialised anti-anginal agents — reflect contemporary evidence-based combination therapy strategies. Selection among these options requires individual patient assessment integrating blood pressure severity, comorbidities (diabetes, CKD, heart failure, AF), tolerability factors, and concurrent medications.

Evidence Base and Quality Standards

The active ingredients in this product have been evaluated in landmark randomised controlled trials forming the foundation of evidence-based cardiovascular medicine. Major international guidelines from the European Society of Cardiology (ESC/ESH), American College of Cardiology/American Heart Association (ACC/AHA), and National Institute for Health and Care Excellence (NICE) support their use in evidence-based treatment algorithms. GMP-compliant manufacturing ensures consistent product quality, identity, strength, and safety across all manufactured batches. Patients should obtain prescription cardiovascular medications only through licensed pharmacies with valid prescriptions to ensure receipt of authentic, quality-assured products.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.